Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Targeted Oncology|April 3, 2020
Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to IbrutinibShiyu Jiang, Yan Qin, Lin Gui, et al.
Chinese Journal of Cancer|September 16, 2015
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphomaYuankai Shi, Ping Zhou, Xiaohong Han, et al.
Annals of Hematology|October 20, 2023
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort studyQiaofeng Zhong, Haizhu Chen, Daoguang Chen, et al.
Journal of Translational Medicine|October 11, 2019
Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapyXiaohong Han, Ying Han, Qiaoyun Tan, et al.
Zhonghua Yi Xue Za Zhi|April 29, 2016
[Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma]Yu Huang, Shengyu Zhou, Xiaohui He, et al.
Leukemia & Lymphoma|July 13, 2019
Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern eraFei Qi, Bo Chen, Jingjing Wang, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2024
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsQiaoyun Tan, Ruyun Gao, Xiaomei Zhang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|April 19, 2019
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in ChinaYuankai Shi, Ying Han, Jianliang Yang, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphomaXinrui Chen, Yan Qin, Xuemin Xue, et al.
Journal of Translational Medicine|September 21, 2021
Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapyYu Zhou, Shasha Wang, Yunxia Tao, et al.
Pageof 8